跳轉至內容
Merck
全部照片(1)

重要文件

M-072

Supelco

二甲双胍标准液 CRM 盐酸盐 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C4H12ClN5
CAS號碼:
分子量::
165.62
EC號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

品質等級

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol (as free base)

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

pharmaceutical (small molecule)

形式

single component solution

儲存溫度

−20°C

SMILES 字串

Cl.CN(C)C(=N)NC(N)=N

InChI

1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H

InChI 密鑰

OETHQSJEHLVLGH-UHFFFAOYSA-N

基因資訊

一般說明

Snap-N-Spike® 参考溶液适用于临床毒理学中LC-MS/MS或GC/MS研究。二甲双胍是一种抗糖尿病药,其可通过抑制肝脏产生葡萄糖发生作用。该双胍类似物专门用于治疗2型糖尿病。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

L C Morin-Papunen et al.
The Journal of clinical endocrinology and metabolism, 85(9), 3161-3168 (2000-09-22)
Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial. Oral contraceptive pills are commonly used in the
P H Marathe et al.
British journal of clinical pharmacology, 50(4), 325-332 (2000-09-30)
The purpose of this in vivo human study was to assess the effect of altered gastric emptying and gastrointestinal motility on the absorption of metformin in healthy subjects. An open-label, three treatment, three period crossover study was conducted in 11
J De Jager et al.
Journal of internal medicine, 257(1), 100-109 (2004-12-21)
The UK Prospective Diabetes Study (UKPDS) showed that treatment with metformin decreases macrovascular morbidity and mortality independent of glycaemic control. We hypothesized that metformin may achieve this by improving endothelial function and chronic, low-grade inflammation. Data on this issue are
J-D Lalau et al.
Diabetes, obesity & metabolism, 5(2), 93-98 (2003-03-13)
Although pharmacokinetics studies have long suggested a deep compartment for the antidiabetic drug metformin, there is still little information concerning metformin accumulation by individual tissues in man. In the present study, the erythrocyte was chosen to represent this putative deep
P S Gillies et al.
Drugs, 60(2), 333-343 (2000-09-13)
Pioglitazone is an orally administered insulin sensitising thiazolidinedione agent that has been developed for the treatment of type 2 diabetes mellitus. Pioglitazone activates the nuclear peroxisome proliferator activated receptor-gamma (PPAR-gamma), which leads to the increased transcription of various proteins regulating

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務